bioequivalence study definition

bioequivalence study means a study to establish the absence of a statistically significant difference in the rate and extent of absorption of an active ingredient from a pharmaceutical formulation in comparison to the reference formulation having the same active ingredient when administered in the same molar dose under similar conditions;
bioequivalence study means a study to establish the absence of a statistically significant difference in the rate and extent of absorption of an
bioequivalence study shall have the meaning set forth in Section 3.1 of this Agreement.

More Definitions of bioequivalence study

bioequivalence study or "BE Study" means a comparative bioavailability study designed to establish equivalence between a generic medicinal product and a comparator product. Both the clinical and bioanalytical parts of the study must be conducted in Member States;
bioequivalence study means an in vivo pharmacokinetic study to demonstrate Bioequivalence.
bioequivalence study means a study to be carried out by Impax, that is designed to show that the Original Product Manufactured in Impax’s Manufacturing facility in Taiwan is bioequivalent to the Original Product Manufactured in Impax’s Manufacturing facility in Hayward, California. Without limiting the foregoing, the term “Bioequivalence Study” will include any number of such studies to be carried out by Impax which are necessary to establish bioequivalence.
bioequivalence study means, with respect to a Licensed Product, the [***] of such Licensed Product as a Biosimilar to the related Reference Product in a clinical study in healthy volunteers or patients.
bioequivalence study means a special type of study, where two drugs or two sets of formulation of the same drug are compared to show that they have nearly equal bioavailability parameters;

Related to bioequivalence study

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase III Clinical Study means a human clinical study of a product on a sufficient number of subjects that is designed to establish that such product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such product, as described in 21 C.F.R. 312.21(c). 1.185. [***] 1.186. [***]

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.